Liftstream is an executive search recruitment company in the life sciences sector
Durata Therapeutics Names New Board Directors
Authored by James Sheppard
Sarepta’s hopes high for first Duchenne (DMD) therapy
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases
Tagged AVI Biopharma, AVI-7100, Department of Defense, DMD, Duchenne Muscular Dystrophy, Ebola, EMEA, Eteplirsen, exon skipping, FDA, Infectious Disease, Influenza, Liftstream Rare Disease Day, Marburg Virus, NIH Clinical Center in Bethesda, Phase II Trials, PMO Chemistry, Rare Disease Day 2013, RDD13, Sarepta Therapeutics, UCL, University College London, USA
Leave a comment
13 Life Science Leaders to watch in 2013
Authored by Liftstream
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Abbott, AbbVie, Amgen, Angus Russell, AstraZeneca, Bluebird bio, Cancer Vaccine, CEO, Cystic Fibrosis, Dalvir Gill, David Mott, Director General EFPIA, EFPIA, EMEA, Erbitux, FDA, Flemming Ornskov, Foundation Medicine, FoundationOne, Gattex, Gene therapy, Gilead Sciences, Glybera, HCV, Hepatitis, Humira, INSPIRE, Jeff Leiden, Jeremy Levin, John Martin, Kalydeco, Karl-Ludwig Kley, Lotus Tissue Repair, Merck KGaA, Michael Pellini, Natpara, New Enterprise Associates, NP Pharmaceuticals, oncology, Orphan drugs, Pascal Soriot, rare diseases, Richard Bergstrom, Richard Gonzalez, Shire, Shire Speciality pharma, Sofosbuvir, Stimuvax, Takeda, Teva, TransCelerate, Ultragenyx, uniQure, Vertex Pharmaceuticals, Vyvanse
Leave a comment
Developing Medical Devices for use in Rare Diseases
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases
Tagged Amyotrophic Lateral Sclerosis (ALS), BSD Medical Corporation, EMA, EMEA, europe, EURORDIS, FDA, HDE, Humanitarian Device Exemption, Medical Devices, Medtronic, Mesomark, Orphan Devices, pricing, rare diseases, Reimbursement, SYNAPSE Biomedical, US FDA
Leave a comment